IP Library › Granted Patent US 9,663,580
Granted Patent B2
US 9,663,580 · App. 15/292,710 · Granted May 30, 2017

Antibodies against human CSF-1R and uses thereof

Inventors: Nikolaos Dimoudis (Wielenbach, DE); Georg Fertig (Penzberg, DE); Alexander Fidler (Penzberg, DE); Klaus Kaluza (Weilheim, DE); Marlene Thomas (Penzberg, DE); Carola Ries (Penzberg, DE); Stefan Seeber (Penzberg, DE); Martin Lanzendoerfer (Tutzing, DE)
Assignee: HOFFMANN-LA ROCHE INC.
C07K16/2866A61K2039/505C07K2317/21C07K2317/24C07K2317/31C07K2317/56C07K2317/565C07K2317/567C07K2317/622C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,580
App. No.
15/292,710
Granted
May 30, 2017
Kind
B2
Abstract

The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims (20)

1. An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 69, a CDR2 region comprising SEQ ID NO: 70, and a CDR1 region comprising SEQ ID NO: 71, and the light chain variable domain comprises a CDR3 region comprising SEQ ID NO:72, a CDR2 region comprising SEQ ID NO: 73, and a CDR1 region comprising SEQ ID NO: 74.

2. A pharmaceutical composition comprising an antibody according to claim 1 .

3. The pharmaceutical composition according to claim 2 , wherein said antibody is formulated in a pharmaceutically acceptable carrier.

4. The antibody according to claim 1 , wherein the antibody is human IgG1 subclass or is of human IgG4 subclass.

5. The antibody according to claim 1 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.

6. A pharmaceutical composition comprising an antibody according to claim 5 .

7. The antibody according to claim 1 , wherein the antibody is an antigen binding fragment.

8. A pharmaceutical composition comprising an antibody according to claim 7 .

9. The antibody according to claim 1 , wherein the antibody is a monoclonal antibody.

10. A pharmaceutical composition comprising an antibody according to claim 9 .

11. An isolated antibody binding to human CSF-I R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises SEQ ID NO: 75 and the light chain variable domain comprises SEQ ID NO: 76.

12. A pharmaceutical composition comprising an antibody according to claim 11 .

13. The pharmaceutical composition according to claim 12 , wherein said antibody is formulated in a pharmaceutically acceptable carrier.

14. The antibody according to claim 11 , wherein the antibody is human IgG1 subclass or is of human IgG4 subclass.

15. The antibody according to claim 11 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.

16. A pharmaceutical composition comprising an antibody according to claim 15 .

17. The antibody according to claim 11 , wherein the antibody is an antigen binding fragment.

18. A pharmaceutical composition comprising an antibody according to claim 17 .

19. The antibody according to claim 11 , wherein the antibody is a monoclonal antibody.

20. A pharmaceutical composition comprising an antibody according to claim 19 .

Priority Claims (2)
EP 09015310 · Dec 10, 2009 · regional
EP 10173407 · Aug 19, 2010 · regional
Continuity (3)
Division 14640183 · Mar 6, 2015
Division 12962445 · Dec 7, 2010
Related Publication 20170029517A1 · Feb 2, 2017